Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:IMTX NASDAQ:MIRM NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$14.53-3.5%$16.88$13.50▼$25.67$3.47B0.473.16 million shs3.18 million shsIMTXImmatics$8.73-3.0%$6.27$3.30▼$11.40$1.06B1.21784,789 shs2.01 million shsMIRMMirum Pharmaceuticals$71.75-1.7%$67.76$36.88▼$78.10$3.60B0.81549,024 shs779,857 shsSRRKScholar Rock$35.19+1.5%$33.91$6.76▼$46.98$3.38B0.421.44 million shs1.26 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+2.66%-3.90%-12.80%-17.74%-23.87%IMTXImmatics+5.63%+22.78%+76.82%+59.57%-19.71%MIRMMirum Pharmaceuticals-0.42%-1.70%-1.18%+46.20%+81.95%SRRKScholar Rock-6.87%+2.85%+6.22%-1.90%+365.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$14.53-3.5%$16.88$13.50▼$25.67$3.47B0.473.16 million shs3.18 million shsIMTXImmatics$8.73-3.0%$6.27$3.30▼$11.40$1.06B1.21784,789 shs2.01 million shsMIRMMirum Pharmaceuticals$71.75-1.7%$67.76$36.88▼$78.10$3.60B0.81549,024 shs779,857 shsSRRKScholar Rock$35.19+1.5%$33.91$6.76▼$46.98$3.38B0.421.44 million shs1.26 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+2.66%-3.90%-12.80%-17.74%-23.87%IMTXImmatics+5.63%+22.78%+76.82%+59.57%-19.71%MIRMMirum Pharmaceuticals-0.42%-1.70%-1.18%+46.20%+81.95%SRRKScholar Rock-6.87%+2.85%+6.22%-1.90%+365.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6790.41% UpsideIMTXImmatics 2.86Moderate Buy$15.0071.82% UpsideMIRMMirum Pharmaceuticals 3.18Buy$76.506.62% UpsideSRRKScholar Rock 3.23Buy$46.4031.86% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, ADMA, SRRK, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/25/2025MIRMMirum PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/24/2025SRRKScholar RockPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$52.00 ➝ $51.009/24/2025MIRMMirum PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/24/2025MIRMMirum PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.009/24/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $44.009/23/2025SRRKScholar RockHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $44.009/18/2025IMTXImmaticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.009/17/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/16/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/15/2025SRRKScholar RockLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/15/2025SRRKScholar RockLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$51.00(Data available from 10/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M8.13$0.54 per share27.08$1.48 per share9.82IMTXImmatics$168.65M6.29$0.25 per share34.87$5.12 per share1.71MIRMMirum Pharmaceuticals$336.89M10.70N/AN/A$4.70 per share15.27SRRKScholar Rock$33.19M101.92N/AN/A$3.94 per share8.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8616.9021.06N/A44.06%41.01%28.47%11/6/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)Latest IMTX, ADMA, SRRK, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78IMTXImmaticsN/A8.808.80MIRMMirum Pharmaceuticals1.213.132.97SRRKScholar Rock0.216.336.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%IMTXImmatics64.41%MIRMMirum PharmaceuticalsN/ASRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%IMTXImmatics3.30%MIRMMirum Pharmaceuticals14.36%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million230.28 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableIMTX, ADMA, SRRK, and MIRM HeadlinesRecent News About These CompaniesAMI Asset Management Corp Invests $1.05 Million in Scholar Rock Holding Corporation $SRRKOctober 2 at 6:34 AM | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives $46.40 Average PT from BrokeragesOctober 2 at 2:43 AM | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Trading Down 4.3% - What's Next?October 1 at 2:40 PM | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Rating of "Buy" by AnalystsSeptember 29 at 2:11 AM | marketbeat.comLeerink Partnrs Raises Earnings Estimates for Scholar RockSeptember 28, 2025 | americanbankingnews.comScholar Rock FY2025 EPS Forecast Reduced by HC WainwrightSeptember 27, 2025 | americanbankingnews.comInvestors Purchase High Volume of Scholar Rock Put Options (NASDAQ:SRRK)September 27, 2025 | americanbankingnews.comLeerink Partnrs Predicts Increased Earnings for Scholar RockSeptember 26, 2025 | marketbeat.comWedbush Has Pessimistic View of Scholar Rock FY2025 EarningsSeptember 26, 2025 | americanbankingnews.comBarclays Has Lowered Expectations for Scholar Rock (NASDAQ:SRRK) Stock PriceSeptember 26, 2025 | americanbankingnews.comScholar Rock Sees Unusually Large Options Volume (NASDAQ:SRRK)September 25, 2025 | marketbeat.comFY2025 EPS Estimates for Scholar Rock Lowered by AnalystSeptember 25, 2025 | marketbeat.comWhat is Wedbush's Estimate for Scholar Rock FY2025 Earnings?September 25, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 3,353 SharesSeptember 25, 2025 | insidertrades.comScholar Rock (NASDAQ:SRRK) Shares Gap Down After Analyst DowngradeSeptember 25, 2025 | americanbankingnews.comScholar Rock price target lowered to $44 from $45 at BarclaysSeptember 24, 2025 | msn.comScholar Rock (NASDAQ:SRRK) Insider Sells $102,836.51 in StockSeptember 24, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Price Target Lowered to $44.00 at BarclaysSeptember 24, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Given New $44.00 Price Target at HC WainwrightSeptember 24, 2025 | americanbankingnews.comScholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility IssuesSeptember 23, 2025 | msn.comScholar Rock stock falls after FDA issues response letter for SMA drugSeptember 23, 2025 | ca.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025The Quiet Before the Catalyst: Vertical Aerospace's Next MoveBy Jeffrey Neal Johnson | September 9, 2025Why Vertical Aerospace Could Lead the eVTOL Market by 2028By Jeffrey Neal Johnson | September 30, 2025IMTX, ADMA, SRRK, and MIRM Company DescriptionsADMA Biologics NASDAQ:ADMA$14.53 -0.52 (-3.46%) Closing price 04:00 PM EasternExtended Trading$14.71 +0.18 (+1.24%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Immatics NASDAQ:IMTX$8.73 -0.27 (-3.00%) Closing price 04:00 PM EasternExtended Trading$8.73 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Mirum Pharmaceuticals NASDAQ:MIRM$71.75 -1.25 (-1.71%) Closing price 04:00 PM EasternExtended Trading$71.74 0.00 (-0.01%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Scholar Rock NASDAQ:SRRK$35.19 +0.51 (+1.47%) Closing price 04:00 PM EasternExtended Trading$35.02 -0.17 (-0.48%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry Rocket Lab's Electron: The Quiet Workhorse Powering Momentum CoreWeave: Why the New King of AI Infrastructure Has Room to Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
